Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
Thirty patients were to be enrolled and 24 patients were actually enrolled into this
open-label, single-arm trial designed to assess the safety and tolerability of oral
deferasirox in adult transfusion dependent myelodysplastic syndrome (MDS) patients with iron
overload. Patients enrolled in this study had low or intermediate (INT-1) risk MDS per
International Prognostic Scoring System (IPSS) criteria. All patients initiated treatment
with 20mg/kg/day deferasirox.
Deferasirox were administered orally once per day for 12 months.